Shield Therapeutics Share Price (STX)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Shield Therapeutics Plc	LSE:STX	London	Ordinary Share	GB00BYV81293	ORD 1.5P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-2.00	-1.08%	182.50	28,526	15:52:38

Bid Price		Offer Price	High Price	Low Price	Open Price
182.00		183.00	184.50	182.50	184.50

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	11.88	-5.15	-2.00		214

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
15:52:39	O	8,000	182.50	GBX

Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Agronomics (ANIC), Valirx (VAL)

Shield Therapeutics (STX) Latest News

Shield Therapeutics News

Date	Time	Source	Headline
26/9/2019	07:02	RNSNON	Shield Therapeutics PLC Investor Presentation
29/8/2019	07:01	RNSNON	Shield Therapeutics PLC Investor presentations
15/8/2019	14:28	ALNC	DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP134,000 In Shares
15/8/2019	10:24	ALNCF	Alliance News Flash Headline
15/8/2019	10:17	UKREG	Shield Therapeutics PLC Director/PDMR Shareholding
07/8/2019	12:02	ALNC	Shield Therapeutics Narrows Interim Losses Amid Expenses Fall
07/8/2019	07:00	UKREG	Shield Therapeutics PLC Half-year Report
31/7/2019	13:21	UKREG	Shield Therapeutics PLC Notice of Results
26/7/2019	14:05	UKREG	Shield Therapeutics PLC Second Price Monitoring Extn
26/7/2019	14:00	UKREG	Shield Therapeutics PLC Price Monitoring Extension

More Shield Therapeutics News

Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Share Charts

1 Year Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

Intraday Shield Therapeutics Chart

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date	Time	Title	Posts
18/10/2019	16:02	Shield Therapeutics	1,871
29/7/2019	13:30	Seagate Technology	2,669

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

Date	Subject
20/10/2019 09:20	Shield Therapeutics Daily Update: Shield Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 184.50p. Shield Therapeutics Plc has a 4 week average price of 180p and a 12 week average price of 103p. The 1 year high share price is 201p while the 1 year low share price is currently 28.50p. There are currently 117,088,657 shares in issue and the average daily traded volume is 102,318 shares. The market capitalisation of Shield Therapeutics Plc is £213,686,799.03. Read Full Thread Reply
10/9/2019 08:59	maximus72: Since flotation, the share price has shown massive movement. Down like a stone after bad FDA rejection and then flying like a bird after broad label approval. Great opportunities for speculators on share values. But when is this company actually going to make money and pay dividends ? Read Full Thread Follow Reply
09/8/2019 10:17	nobbygnome: >> cranky man I don't disagree with your figures. However, the point is that the share price is at 160 odd despite all this value of the drug. That is the fundamental problem with Aim where there are so many undervalued companies. That means there is a possibility that there could be a take out at a price which is too low. Yes the VC may reduce that risk but everyone has a price and it is difficult to predict what they will do. Read Full Thread Follow Reply
07/8/2019 11:01	borromini1: Edison expectation for STX 2019 revenue = 3.14m GBP STX H1 2019 revenue = 2.6m GBP (includes milestone payments) STX H2 2019 revenue expectation = 0.54m GBP or more (pack sales only) Should be easily beaten. Edison current valuation 273m GBP or share price 231p. Read Full Thread Follow Reply
24/7/2019 11:06	borromini1: After the misinterpreted trial results a key impact was that the STX direct sales team was shut down. The result has been a drop in future STX revenue potential as margin has been given away to third party partners like Norgine. The dilemma is how much of the value in the new business strategy and model is already built into the current share price for the stage STX are at. And has the potential for ramping up to higher revenues been pushed further out into the future within a competitive market. That is why the H1 2019 Business Update is important, it will be the first half year results to reflect the revenue potential under the new business model. Again, why is STX delaying the Update release? Read Full Thread Follow Reply
24/7/2019 08:50	maximus72: My own experience has also been a very steep learning curve. I invested quite modestly after flotation of STX as what seemed a decent bet, but just accepted the hit after the FDA rejection last time and held on to the stock and just balanced it with other investments.The fundamentals of a game changing product remain excellent. When the share price hit rock bottom I then invested as a medium term return so on balance overall holdings now look fine. What has suprised me is the extent to which some of the big boys operate in market manipulation. This is clearly apparent. STX is still certainly a fantastic opportunity at the present time but those who win and those who lose define a prudent approach to investment of any category. Read Full Thread Follow Reply
23/7/2019 08:12	borromini1: Since the FDA approval is such a dead certainty it is likely that a large percentage of the uplift is already priced in. In the USA regulatory environment citizens are already encouraged to self medicate with oral iron supplements to a much higher dosage level than in Europe. 50mg per day compared to 14mg per day. Abandoning the direct sales force and giving away a large percentage of a fixed margin had a big impact on STX future revenue levels. STX have not yet released the H1 2019 Business Update, this is the report that will also move the share price. Read Full Thread Follow Reply
19/7/2019 15:30	stevee1234: Hi Nobby, yes agree more buys recently, maybe we're about as low as it gets before more buyers stop the drop. I'm just trying to explain why I believe the share price has moved as it has over the last three weeks. It's a question of "do sellers prompt the share price to drop" or "do price drops prompt holders to sell" obviously a bit of both but on AIM I think the MMs know that when a share has had a good run recently dropping the price can often stimulate profit taking and hence allow them to get some shares back ready for the next upward step. I believe people are more motivated to buy when the chare price rises and sell when the share price falls, hence when stx stalled at 120ish they have been progressively stimulating the market by dropping the price, hopefully in coming weeks they'll be stimulating the market by raising the price. Still as I said everything crossed for the main event hopefully soon. Read Full Thread Follow Reply
18/7/2019 07:44	borromini1: Nobby - This aspect seems obvious and not in the least obscure, it seems the notion that Feraccru is going to eat Ferinject’s lunch is taken as a forgone conclusion by STX and investors and as a result this view has and is being built into the share price. Read Full Thread Follow Reply
14/7/2019 09:58	peachie 74: Few things could really play out here Get FDA approval hopefully. This will attract in Institutional investment. Rising share price leading to... Private investors will get Shield on their radar and do a bit of investigation and realise China potential Takeover potential PT 20 potential All this feeds itself into an ever increasing share price hopefully for all current and future holders Read Full Thread Follow Reply
01/2/2019 10:44	cf456: There's certainly blue sky on the chart to all the way to 110p. And the share price today should actually be above 110p since the reason for the original drop from 110p was completely invalidated in March 2018: --- 5 Feb 18: initial blended top-line data from Ferracru AEGIS-CKD study shows apparent failure to meet primary end-point 16 Mar 18: AEGIS-CKD detailed analysis shows study did in fact meet primary end-point 27 Mar 18: EU extends approved Ferracru indication to all adults with iron deficiency -- So in theory the share price should never have dropped in the first place since the AEGIS-CKD study results were positive all along. As per the most recent presentation: "Investment proposition – the recovery of the business from the consequences of the initial and ultimately incorrect AEGIS-CKD study results have not yet been reflected in the share price" hTTps://www.shieldtherapeutics.com/wp-content/uploads/2019/01/STX-investor-presentation-January-2019.pdf - page 4 Read Full Thread Follow Reply

Shield Therapeutics share price data is direct from the London Stock Exchange

Your Recent History

LSE

STX

Shield The..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20191021 05:30:08